Boston completes $425m divestment to Avista
This article was originally published in Clinica
Boston Scientific has completed the sale of its fluid management and venous access businesses to private New York equity firm Avista Capital Partners for $425m. An agreement for the all-cash deal was originally signed in December (see Clinica No 1287, p 1). The closing of the sale brings about the completion of Boston's plans to divest its five non-core businesses. Boston is currently undergoing major restructuring initiative to pull the company back into profitable growth. The Natick-Massachusetts-based company expects the divestment to result in after-tax gain of around $120m during the first quarter of 2008.
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”